Clinical trials: Impairment, Cognitive
Vascular Dementia, Mild Cognitive Impairment
Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment
This clinical trial evaluates the preliminary effectiveness and safety of Cerogrin, a medical device developed by Neurogrin Inc.
- Trial name
- NCT07149038
- Testing
- Cerogrin
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Neurogrin Inc.
Health, Subjective, Gastrointestinal Dysfunction
Personal Lifestyle Engine (PLX) - Personal Lifestyle Medicine Center (PLMC)
It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory.
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- NCT04007939
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Mild Cognitive Impairment
Navigating the Clinical Research Process for Mild Cognitive Impairment
Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT06207903
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Mild Cognitive Impairment
Efficacy of MEMORMAX in Subjects With MCI
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment.
- Trial name
- ABO-MEMO (NCT03581929)
- Testing
- Memormax
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Aboca Spa Societa' Agricola
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Cognitive Impairment Associated With Schizophrenia (CIAS)
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
- Trial name
- NCT02855411
- Testing
- PF-04958242
- Where
- 16 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Schizophrenia
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with…
- Trial name
- NCT00567203
- Testing
- PF-3463275
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Alzheimer Disease, Cognitive Impairment
The REMIND Study- SPARK Neuro Software Study
The study utilizes investigational software, the SPARK Test, with an FDA-cleared electroencephalography (EEG) amplifier and EEG cap to collect and patient EEG data.
- Trial name
- NCT05406778
- Testing
- SPARK Test
- Where
- 7 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Mild Cognitive Impairment, Alzheimer Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
- Trial name
- NCT06400368
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NeuroVision Imaging
Schizophrenia
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive…
- Trial name
- NCT00077727
- Testing
- Extended-release galantamine hydrobromide
- Volunteers
- 107 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Excessive Daytime Sleepiness, Obstructive Sleep Apnea
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) plus impaired…
- Conditions
- Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
- Trial name
- SHARP (NCT04789174)
- Testing
- Solriamfetol
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 59 people
- Sponsor
- Axsome Therapeutics, Inc.
Mild Cognitive Impairment, Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or…
- Trial name
- NCT01661673
- Testing
- EVP-0962
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- FORUM Pharmaceuticals Inc
Healthy
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.
- Trial name
- NCT04602221
- Testing
- Lamotrigine, BI 409306, BI 425809
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease, Mild Cognitive Impairment
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved…
- Trial name
- NCT01099332
- Testing
- Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adeona Pharmaceuticals
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Hunter Syndrome
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment
The study is an extension of two previous studies (HGT-HIT-046 [NCT01506141] and SHP609-302 [NCT02412787]). Participants must have completed one of the previous studies.
- Trial name
- NCT06031259
- Testing
- Idursulfase-IT, Elaprase
- Where
- 4 sites in Canada, France
- Volunteers
- 6 people
- Sponsor
- Takeda
Early Alzheimer's Disease
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical…
- Trial name
- Clarity AD (NCT03887455)
- Testing
- Lecanemab IV, Lecanemab SC
- Where
- 247 sites in United States, Australia and 12 more
- Volunteers
- 1,906 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort.
- Trial name
- NCT04437511
- Testing
- Donanemab
- Where
- 274 sites in United States, Australia and 7 more
- Volunteers
- 1,736 people
- Sponsor
- Eli Lilly and Company
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals